Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Bonache, Sandra|||0000-0002-7395-8143
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rueda, Oscar M.
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Polanska, Urszula|||0000-0003-1017-594X
  • Jones, Gemma|||0000-0002-7567-681X
  • Kristel, Petra
  • de Bustos, L.
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Montalban, Gemma|||0000-0002-6958-4759
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Fasani, Roberta|||0000-0003-1630-9988
  • Jiménez, Jose|||0000-0002-2576-1776
  • Howat, William J.
  • Dougherty, Brian|||0000-0002-0093-1142
  • Vivancos, Ana|||0000-0003-2888-6512
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Rubio Rodríguez, Isabel Teresa
  • Oaknin, Ana|||0000-0002-3592-7194
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Jonkers, Jos|||0000-0002-9264-9792
  • Diez, Orland|||0000-0001-7339-0570
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1 -loss in 20% and RAD51 -amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation

  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Ducy, Mandy
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Pellegrino, Benedetta
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Bonache, Sandra|||0000-0002-7395-8143
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Gómez Pardo, Patricia
  • Vidal, Marc
  • Peg, Vicente|||0000-0002-5203-6166
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Dellaire, Graham
  • Simard, Jacques|||0000-0001-6906-3390
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Rubio, Isabel T.|||0000-0003-0035-0679
  • Dientsmann, Rodrigo
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Déas, Olivier
  • Jonkers, Jos|||0000-0002-9264-9792
  • Masson, Jean-Yves
  • Cairo, Stefano
  • Judde, Jean-Gabriel
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. We evaluated the activity of the i olaparib in patient-derived tumor xenografts (s) from breast cancer () patients and investigated mechanisms of sensitivity through exome sequencing, 1 promoter methylation analysis, and immunostaining of proteins, including 51 nuclear foci. In an independent panel, the predictive capacity of the 51 score and the homologous recombination deficiency () score were compared. To examine the clinical feasibility of the 51 assay, we scored archival breast tumor samples, including 2-related hereditary cancers. The 51 score was highly discriminative of i sensitivity versus PARPi resistance in s and outperformed the genomic test. In clinical samples, all 2-related tumors were classified as -deficient by the 51 score. The functional biomarker 51 enables the identification of i-sensitive and broadens the population who may benefit from this therapy beyond 1/2-related cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra, Violeta|||0000-0001-6620-1065
  • Wang, Anderson T.|||0000-0002-3571-5095
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Polanska, Urszula|||0000-0003-1017-594X
  • Palafox, Marta|||0000-0002-1762-3250
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Jones, Gemma|||0000-0002-7567-681X
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Armenia, Joshua|||0000-0002-9005-7769
  • Michopoulos, Filippos|||0000-0002-3667-6147
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Brough, Rachel|||0000-0002-1862-7130
  • Gulati, Aditi|||0000-0001-7476-2524
  • Pettitt, Stephen|||0000-0003-3313-3857
  • Bulusu, Krishna C.|||0000-0002-5092-6640
  • Nikkila, Jenni|||0000-0003-1380-8781
  • Wilson, Zena|||0000-0001-8811-4069
  • Hughes, Adina|||0000-0002-5711-627X
  • Wijnhoven, Paul W.G.|||0000-0002-5489-3006
  • Ahmed, Ambar|||0000-0002-5890-5035
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lau, Alan|||0000-0003-1055-9812
  • Critchlow, Susan|||0000-0002-4647-8988
  • Dougherty, Brian|||0000-0002-0093-1142
  • Caldas, Carlos|||0000-0003-3547-1489
  • Mills, Gordon|||0000-0002-0144-9614
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Forment, Josep V.|||0000-0002-7797-2583
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Lord, Christopher J.|||0000-0002-3226-0515
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • O'Connor, Mark J.|||0000-0003-1823-625X
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. We analyzed breast and ovarian patientderived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.